• S N Tereshchenko, I A Cheremisina, and A A Safiullina.
• Chazov National Medical Research Center of Cardiology.
• Terapevt Arkh. 2022 May 26; 94 (4): 517-523.

AimTo study the efficacy and safety of exogenous phosphocreatine (EF) in patients with chronic heart failure (CHF).Materials And MethodsThe all-Russian prospective observational study BYHEART included 842 patients who were treated with EF. Before and after the course of EF therapy, the following studies were conducted: a questionnaire on the Minnesota Living with Heart Failure Questionnaire (MLHFQ) and a clinical condition assessment scale (SHOCK), transthoracic echocardiography with an assessment of the left ventricular ejection fraction, a 6-minute walk test, determination of the level of pro-natriuretic N-terminal peptide (NT-proBNP), glomerular filtration rate. All patients before the course of EF received long-term optimal drug therapy of CHF.ResultsStatistical analysis was carried out in the general group of patients (n=842), as well as in groups of patients A (n=418, the course of treatment of EF is less than 20 g /course) and group B (n=424, the course of treatment of EF is greater than or equal to 20 g/course). The results obtained demonstrate a positive effect of the use of the course of therapy of EF in patients with CHF on the quality of life (QOL), reverse left ventricular remodeling, functional class of CHF, as well as the concentration of NT-pro-BNP, especially in the group of patients who received more than 20 grams of the medication.ConclusionThe use of EF is a promising pharmacological method of treatment in addition to optimal drug therapy in patients with CHF.

16 keywords...

hide…